• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Moves Higher; Oxford Industries Shares Fall After Q4 Results

    4/1/24 1:47:57 PM ET
    $AEON
    $CXAI
    $DOMA
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology
    Get the next $AEON alert in real time by email

    U.S. stocks traded lower midway through trading, with the Dow Jones falling over 300 points on Monday.

    The Dow traded down 0.79% to 39,492.80 while the NASDAQ fell 0.22% to 16,344.11. The S&P 500 also fell, dropping, 0.45% to 5,230.46.

    Check This Out: Jim Cramer Likes Crown Castle, But Can't Recommend Archer Aviation: It Has 'No Earnings Power'

     

    Leading and Lagging Sectors

     

    Communication services shares jumped by 1.1% on Monday.

    In trading on Monday, real estate shares fell by 1.8%.

     

    Top Headline

     

    Shares of Oxford Industries, Inc. (NYSE:OXM) fell more than 4% on Monday after the company reported downbeat financial results for its fourth quarter and issued weak guidance for the first quarter on Thursday.

     

    Equities Trading UP

     

    CXApp Inc. (NASDAQ:CXAI) shares shot up 143% to $5.95 after the company announced a partnership with Google Cloud for acceleration of the CXAI platform.

    Shares of Sunshine Biopharma, Inc. (NASDAQ:SBFM) got a boost, surging 87% to $0.1138 after the company FY23 operating results.

    Doma Holdings Inc. (NYSE:DOMA) shares were also up, gaining 34% to $6.07 after the company entered a merger transaction with TRG to go private at $6.29 per share in cash.

     

    Equities Trading DOWN

     

    Nuvve Holding Corp. (NASDAQ:NVVE) shares dropped 29% to $0.7798 after the company reported worse-than-expected fourth-quarter financial results.

    Shares of AEON Biopharma, Inc. (NYSE:AEON) were down 41% to $6.86 after the company reported a fourth-quarter loss of 71 cents per share.

    Disc Medicine, Inc. (NASDAQ:IRON) was down, falling 50% to $31.25 after the company reported topline results from the Phase 2 AURORA study of bitopertin in patients with EPP.

    Also Check This Out: Bitcoin Trades Above $70,000 Following GDP, Jobless Claims Data; GateToken Emerges As Top Gainer

     

    Commodities

     

    In commodity news, oil traded up 0.9% to $83.92 while gold traded up 0.9% at $2,259.20.

    Silver traded up 0.8% to $25.12 on Monday, while copper rose 1% to $4.0475.


    Economics

     

    The ISM Manufacturing PMI rose to 50.3 in March versus 47.8 in February and topping market estimates of 48.4.

    U.S. construction spending fell by 0.3% from the prior month in February.

    The S&P Global manufacturing PMI was revised lower to 51.9 in March compared to a preliminary reading of 52.5.

    Now Read This: $5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying

    Get the next $AEON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEON
    $CXAI
    $DOMA
    $IRON

    CompanyDatePrice TargetRatingAnalyst
    Oxford Industries Inc.
    $OXM
    3/27/2026$40.00 → $36.00Market Perform
    Telsey Advisory Group
    Oxford Industries Inc.
    $OXM
    1/13/2026$35.00 → $40.00Market Perform
    Telsey Advisory Group
    Oxford Industries Inc.
    $OXM
    12/11/2025$52.00 → $35.00Market Perform
    Telsey Advisory Group
    Oxford Industries Inc.
    $OXM
    11/25/2025$35.00Sell → Neutral
    Citigroup
    Disc Medicine Inc.
    $IRON
    11/3/2025$125.00Buy
    Stifel
    Disc Medicine Inc.
    $IRON
    7/21/2025$86.00Buy
    Truist
    Disc Medicine Inc.
    $IRON
    7/3/2025$85.00Overweight
    Morgan Stanley
    Disc Medicine Inc.
    $IRON
    6/11/2025$89.00Strong Buy
    Raymond James
    More analyst ratings

    $AEON
    $CXAI
    $DOMA
    $IRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on Oxford Industries with a new price target

    Telsey Advisory Group reiterated coverage of Oxford Industries with a rating of Market Perform and set a new price target of $36.00 from $40.00 previously

    3/27/26 7:58:08 AM ET
    $OXM
    Garments and Clothing
    Industrials

    Telsey Advisory Group reiterated coverage on Oxford Industries with a new price target

    Telsey Advisory Group reiterated coverage of Oxford Industries with a rating of Market Perform and set a new price target of $40.00 from $35.00 previously

    1/13/26 8:19:44 AM ET
    $OXM
    Garments and Clothing
    Industrials

    Telsey Advisory Group reiterated coverage on Oxford Industries with a new price target

    Telsey Advisory Group reiterated coverage of Oxford Industries with a rating of Market Perform and set a new price target of $35.00 from $52.00 previously

    12/11/25 7:59:31 AM ET
    $OXM
    Garments and Clothing
    Industrials

    $AEON
    $CXAI
    $DOMA
    $IRON
    SEC Filings

    View All

    AEON Biopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - AEON Biopharma, Inc. (0001837607) (Filer)

    4/3/26 4:05:14 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Sunshine Biopharma Inc.

    10-K - Sunshine Biopharma Inc. (0001402328) (Filer)

    4/3/26 11:58:23 AM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Nuvve Holding Corp.

    10-K - Nuvve Holding Corp. (0001836875) (Filer)

    3/31/26 5:18:14 PM ET
    $NVVE
    Electrical Products
    Industrials

    $AEON
    $CXAI
    $DOMA
    $IRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bencich John

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    4/3/26 6:22:30 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Bencich John

    3 - AEON Biopharma, Inc. (0001837607) (Issuer)

    4/3/26 6:22:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kelly Michelle M

    4 - OXFORD INDUSTRIES INC (0000075288) (Issuer)

    3/20/26 6:57:17 PM ET
    $OXM
    Garments and Clothing
    Industrials

    $AEON
    $CXAI
    $DOMA
    $IRON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

    IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that, on April 2, 2026, in connection with the appointment of John Bencich as Chief Financial Officer, the Company's Compensation Committee of the Board of Directors (the "Compensation Committee") approved the grant of inducement awards. The Compensation Committee approved the grant to Mr. Bencich of 754,717 restricted stock units ("RSUs") under AEON's 2025 Employment Inducement Incentive Award Plan (the "Induce

    4/3/26 4:10:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards

    IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that on March 31, 2026, it received a notice (the "Notice") from NYSE American LLC ("NYSE American") indicating that, following its year-end financial results, the Company is not in compliance with an additional continued listing standard set forth in the NYSE American Company Guide (the "Company Guide"). As previously disclosed, on February 3, 2025, the Company received a notice (the "Original Notice") that it

    4/3/26 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvve Provides Fourth Quarter and Full Year 2025 Financial Update

    Investor Conference Call to be Held Today at 5:00 PM Eastern Time (2:00 PM PT) Nuvve Holding Corp. (Nuvve) (NASDAQ:NVVE), a global leader in advanced energy storage, grid modernization solutions and vehicle-to-grid (V2G) technology, today provided a fourth quarter and full-year 2025 financial update. Fourth Quarter Highlights and Recent Developments We raised $8.1 million in gross proceeds through a private preferred stock offering, warrants exercises and debt obligations during the fourth quarter of 2025 to support our operations and growth initiatives Total revenues were $1.9 million for the fourth quarter of 2025 compared to $1.8 million for the fourth quarter 2024 Gross pro

    3/31/26 4:30:00 PM ET
    $NVVE
    Electrical Products
    Industrials

    $AEON
    $CXAI
    $DOMA
    $IRON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Chubb Thomas Caldecot Iii bought $175,585 worth of shares (5,000 units at $35.12), increasing direct ownership by 28% to 22,709 units (SEC Form 4)

    4 - OXFORD INDUSTRIES INC (0000075288) (Issuer)

    12/12/25 5:52:12 PM ET
    $OXM
    Garments and Clothing
    Industrials

    CEO and President Chubb Thomas Caldecot Iii disposed of 34,650 shares, acquired 34,650 shares and bought $12,130 worth of shares (318 units at $38.19), increasing direct ownership by 59% to 94,031 units (SEC Form 4)

    4 - OXFORD INDUSTRIES INC (0000075288) (Issuer)

    8/4/25 4:53:15 PM ET
    $OXM
    Garments and Clothing
    Industrials

    CEO, Johnny Was Trauber Robert S. bought $413,750 worth of shares (10,000 units at $41.38), increasing direct ownership by 297% to 13,364 units (SEC Form 4)

    4 - OXFORD INDUSTRIES INC (0000075288) (Issuer)

    6/20/25 8:00:16 AM ET
    $OXM
    Garments and Clothing
    Industrials

    $AEON
    $CXAI
    $DOMA
    $IRON
    Financials

    Live finance-specific insights

    View All

    AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program

    – Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® –  – Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a clear framework for advancing the comparative analytical plan for ABP-450 biosimilar program – – Strengthened balance sheet through $6 million PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90% – – Appointed John Bencich as Chief Financial Officer, adding significant capital markets and strategic leadership experience – IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (

    3/30/26 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports Fourth Quarter and Full-Year Fiscal 2025 Results

    Initiates fiscal 2026 guidance reflecting meaningfully improved profitability on modest sales growth driven by improvement at Tommy Bahama.Fiscal 2026 guidance includes revenues of $1.475 billion to $1.530 billion, GAAP EPS of $1.83 to $2.43 and adjusted EPS of $2.10 to $2.70; EPS expectations assume IEEPA tariff rates continued for balance of year.Increases quarterly dividend to $0.70 per share. ATLANTA, March 26, 2026 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its fourth quarter and full fiscal year 2025 ended January 31, 2026 and initiated guidance for the first quarter and full fiscal year 2026. Consolidated net sales in the fourth qu

    3/26/26 4:05:00 PM ET
    $OXM
    Garments and Clothing
    Industrials

    Nuvve to Provide Fourth Quarter Ended December 31, 2025, Financial Update

    Investor Conference Call to be Held Tuesday, March 31, 2026, at 5:00 PM Eastern Time (2:00 PM PT) Nuvve Holding Corp. ("Nuvve") (NASDAQ:NVVE), a global leader in grid modernization and vehicle-to-grid (V2G) technology, will provide Fourth quarter ended December 31, 2025, update on Tuesday, March 31, 2026. Conference Call Details Nuvve will hold a conference call to review its financial results for the fourth quarter ended December 31, 2025, along with other company developments at 5:00 PM Eastern Time (2:00 PM PT), Tuesday, March 31, 2026. To participate in the call, please dial (888) 349-0097 or (412) 902-4245; Passcode: 7091129, or register for and listen via a live webcast, which

    3/26/26 8:00:00 AM ET
    $NVVE
    Electrical Products
    Industrials

    $AEON
    $CXAI
    $DOMA
    $IRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    11/14/24 5:44:55 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by AEON Biopharma Inc.

    SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)

    11/14/24 5:05:14 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    11/14/24 4:33:10 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEON
    $CXAI
    $DOMA
    $IRON
    Leadership Updates

    Live Leadership Updates

    View All

    AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

    IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that, on April 2, 2026, in connection with the appointment of John Bencich as Chief Financial Officer, the Company's Compensation Committee of the Board of Directors (the "Compensation Committee") approved the grant of inducement awards. The Compensation Committee approved the grant to Mr. Bencich of 754,717 restricted stock units ("RSUs") under AEON's 2025 Employment Inducement Incentive Award Plan (the "Induce

    4/3/26 4:10:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AEON Biopharma Appoints John Bencich as Chief Financial Officer

    IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced the appointment of John Bencich as Chief Financial Officer. Mr. Bencich joins AEON at a pivotal stage in the Company's evolution as it prepares to execute through its next phase of critical regulatory milestones. "John's appointment represents an important step forward for AEON as we enter a period of accelerated execution," said Rob Bancroft, President and Chief Executive Officer of AEON. "His d

    3/9/26 4:05:00 PM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

    WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Lisa Amaya Price, MBA as the company's Chief Human Resources (HR) Officer. Ms. Amaya Price brings more than 25 years of experience in human resources and organizational leadership, including at multiple commercial-stage companies. "As we move towards commercialization, we have meaningfully increased hiring to support these efforts and Lisa will play a central role in building a strong, scal

    1/12/26 4:30:00 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care